Chemours director granted 7,182 company shares

CRANSTON MARY B reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

CRANSTON MARY B reported acquisition or exercise transactions in this Form 4 filing.

Chemours Co director Mary B. Cranston received an equity grant of 7,182 shares of common stock on May 6. The award was granted at no cash cost to her, reflecting stock-based compensation rather than an open-market purchase.

After this grant and an adjustment to correct an administrative error in prior filings, her direct and deferred holdings now total 106,830.0129 shares, including deferred stock units and related dividend equivalent units.

Insider Trade Summary

Grant/Award: 7,182 shares

Grant/Award 1 txn

Insider CRANSTON MARY B

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,182	$0.00	$0.00

Holdings After Transaction: Common Stock — 106,830.0129 shares (Direct)

Footnotes (2)

1. F1. The total holdings have been adjusted to correct an administrative error in prior Form 4s.
2. F2. Includes deferred stock units and dividend equivalent units.

Key Figures

Equity grant: 7,182 shares Grant price per share: $0.0000 per share Total holdings after transaction: 106,830.0129 shares +1 more

4 metrics

Equity grant 7,182 shares Common Stock award on May 6, 2026

Grant price per share $0.0000 per share Indicates stock-based compensation, not market purchase

Total holdings after transaction 106,830.0129 shares Includes deferred stock units and dividend equivalent units

Acquire transactions 1 transaction Form 4 transactionSummary acquireCount

Key Terms

deferred stock units, dividend equivalent units, administrative error, Form 4

4 terms

deferred stock units financial

"Includes deferred stock units and dividend equivalent units."

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

dividend equivalent units financial

"Includes deferred stock units and dividend equivalent units."

Dividend equivalent units are bookkeeping credits that mirror cash dividends paid on actual shares, granted to holders of stock-based awards such as restricted stock units or deferred compensation. They matter to investors because they increase a company’s reported employee compensation cost and can lead to issuance of more shares or cash payouts over time, similar to extra pay linked to ownership that affects shareholder dilution and corporate cash flow.

administrative error regulatory

"adjusted to correct an administrative error in prior Form 4s."

Form 4 regulatory

"administrative error in prior Form 4s."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Chemours (CC) director Mary B. Cranston report in this Form 4?

Mary B. Cranston reported receiving an equity grant of 7,182 Chemours common shares. The transaction reflects a stock-based compensation award, not a market purchase, and increases her total direct and deferred holdings to 106,830.0129 shares following an administrative correction.

Was the Chemours (CC) director’s 7,182-share award an open-market stock purchase?

No, the 7,182 Chemours shares were acquired as a grant, not bought in the open market. The Form 4 uses code “A” for a grant, with a price of $0.0000 per share, indicating compensation rather than a discretionary stock purchase.

How many Chemours (CC) shares does Mary B. Cranston hold after this transaction?

After the award, Mary B. Cranston holds 106,830.0129 Chemours shares in total. This figure includes her direct holdings plus deferred stock units and dividend equivalent units, reflecting both current shares and deferred equity-based compensation reported in the Form 4.

Did the Chemours (CC) Form 4 mention any corrections to prior reports?

Yes, a footnote states that total holdings were adjusted to correct an administrative error in prior Form 4s. This means earlier filings understated or overstated her position, and the current 106,830.0129-share total is intended to reflect the corrected amount.

What are the deferred stock and dividend equivalent units in this Chemours (CC) filing?

The Form 4 notes that Cranston’s total includes deferred stock units and dividend equivalent units. Deferred units represent stock-based compensation to be delivered later, while dividend equivalent units track dividends on those deferred units as additional credited units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CRANSTON MARY B

(Last) (First) (Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/06/2026		A		7,182	A	$0	106,830.0129(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The total holdings have been adjusted to correct an administrative error in prior Form 4s.

2. Includes deferred stock units and dividend equivalent units.

	/s/ Eric Stein, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)